Biomedical Engineering Reference
In-Depth Information
4. Kenanova VE, Olafsen T, Salazar FB, Williams LE, Knowles
S, Wu AM. (2010) Tuning the serum persistence of human
serum albumin domain III: diabody fusion proteins. Protein
Eng. Des. Sel. 23, 789-798.
5. Kolmar H. (2008) Alternative binding proteins: biological
activity and therapeutic potential of cystine-knot minipro-
teins. FEBS J. 275, 2684-2690.
6. McGregor DP. (2008) Discovering and improving novel
peptide therapeutics. Curr. Opin. Pharmacol. 8, 616-619.
7. Nuttall SD, Walsh RB. (2008) Display scaffolds: protein
engineering for novel therapeutics. Curr. Opin. Pharmacol.
8, 609-615.
8. Rothe A, Hosse RJ, Power BE. (2006) Ribosome display for
improved biotherapeutic molecules. Expert Opin. Biol. Ther.
6, 177-187.
9. Schellenberger V, Wang CW, Geething NC, Spink BJ,
Campbell A, To W, et al. (2009) A recombinant polypeptide
extends the in vivo half-life of peptides and proteins in a
tunable manner. Nat. Biotechnol. 27, 1186-1190.
10. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A,
Tam AW, et al. (1984) Human epidermal growth factor
receptor cDNA sequence and aberrant expression of the
amplified gene in A431 epidermoid carcinoma cells. Nature
309, 418-425.
11. Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B,
Yarchoan R, et al. (1985) Soluble interleukin 2 receptors are
released from activated human lymphoid cells in vitro. J.
Immunol. 135, 3172-3177.
12. Levine SJ. (2008) Molecular mechanisms of soluble cytokine
receptor generation. J. Biol. Chem. 283, 14177-14181.
13. Engelmann H, Aderka D, Rubinstein M, Rotman D,
Wallach D. (1989) A tumor necrosis factor-binding protein
purified to homogeneity from human urine protects cells
from tumor necrosis factor toxicity. J. Biol. Chem. 264,
11974-11980.
14. Marcon L, Fritz ME, Kurman CC, Jensen JC, Nelson DL.
(1988) Soluble Tac peptide is present in the urine of normal
individuals and at elevated levels in patients with adult T cell
leukaemia (ATL). Clin. Exp. Immunol. 73, 29-33.
15. Novick D, Engelmann H, Wallach D, Rubinstein M. (1989)
Soluble cytokine receptors are present
20. Fernandez-Botran R. (2000) Soluble cytokine receptors:
novel immunotherapeutic agents. Expert Opin. Investig.
Drugs 9, 497-514.
21. Mantovani A, Bonecchi R, Martinez FO, Galliera E, Perrier P,
Allavena P, et al. (2003) Tuning of innate immunity and
polarized responses by decoy receptors. Int. Arch. Allergy
Immunol. 132, 109-115.
22. Eissner G, Kolch W, Scheurich P. (2004) Ligands working as
receptors: reverse signaling by members of the TNF super-
family enhance the plasticity of the immune system. Cytokine
Growth Factor Rev. 15, 353-366.
23. Kopf M, Bachmann MF, Marsland BJ. (2010) Averting
inflammation by targeting the cytokine environment. Nat.
Rev. Drug Discov. 9, 703-718.
24. Shui JW, Steinberg MW, Kronenberg M. (2011) Regulation
of inflammation, autoimmunity, and infection immunity
by HVEM-BTLA signaling. J. Leukoc. Biol. 89, 517-523.
25. Treiger BF, Leonard WJ, Svetlik P, Rubin LA, Nelson DL,
Greene WC. (1986) A secreted form of the human interleukin
2 receptor encoded by an “anchor minus” cDNA. J. Immunol.
136, 4099-4105.
26. Kondo N, Kondo S, Shimizu A, Honjo T, Hamuro J. (1988) A
soluble 'anchorminus' interleukin 2 receptor suppresses in
vitro interleukin 2-mediated immune responses. Immunol.
Lett. 19, 299-307.
27. Fernandez-Botran R. (1991) Soluble cytokine receptors: their
role in immunoregulation. FASEB J. 5, 2567-2574.
28. Gershoni JM. (2008) Molecular decoys: antidotes, therapeu-
tics and immunomodulators. Curr. Opin. Biotechnol. 19,
644-651.
29. Corradini E, Babitt JL, Lin HY. (2009) The RGM/DRAGON
family of BMP co-receptors. Cytokine Growth Factor Rev.
20, 389-398.
30. Bizet AA, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J,
Finnson KW, et al. (2011) The TGF-beta co-receptor, CD109,
promotes internalization and degradation of TGF-beta recep-
tors. Biochim. Biophys. Acta 1813, 742-753.
31. M. Ehrlich, D. Horbelt, B. Marom, P. Knaus, Y. I. Henis.
(2011). Homomeric and heteromeric complexes among
TGF-beta and BMP receptors and their roles in signaling.
Cellular signalling, 23, 1424-1432.
32. Onichtchouk D, Chen YG, Dosch R, Gawantka V, Delius H,
Massague J, et al. (1999) Silencing of TGF-beta signalling by
the pseudoreceptor BAMBI. Nature 401, 480-485.
33. O'Neill LA. (2003) SIGIRR puts the brakes on Toll-like
receptors. Nat. Immunol. 4, 823-824.
34.WaldD,QinJ,ZhaoZ,QianY,NaramuraM,TianL,etal.
(2003) SIGIRR, a negative regulator of Toll-like
receptor-interleukin 1 receptor signaling. Nat. Immunol.
4, 920-927.
35. Colotta F, Re F, Muzio M, Bertini R, Polentarutti N, Sironi M,
et al. (1993) Interleukin-1 type II receptor: a decoy target for
IL-1 that is regulated by IL-4. Science 261, 472-475.
36. Sims JE, Smith DE. (2010) The IL-1 family: regulators of
immunity. Nat. Rev. Immunol. 10, 89-102.
in normal human
urine. J. Exp. Med. 170, 1409-1414.
16. Schall TJ, Lewis M, Koller KJ, Lee A, Rice GC, Wong GH,
et al. (1990) Molecular cloning and expression of a receptor
for human tumor necrosis factor. Cell 61, 361-370.
17. Seckinger P, Isaaz S, Dayer JM. (1989) Purification and
biologic characterization of a specific tumor necrosis factor
alpha inhibitor. J. Biol. Chem. 264, 11966-11973.
18. Zupan AA, Osborne PA, Smith CE, Siegel NR, Leimgruber
RM, Johnson EM, Jr. (1989) Identification, purification,
and characterization of truncated forms of the human
nerve growth factor
receptor.
J. Biol. Chem. 264,
11714-11720.
19. Fernandez-Botran R. (1999) Soluble cytokine receptors:
basic immunology and clinical applications. Crit. Rev.
Clin. Lab. Sci. 36, 165-224.
Search WWH ::
Custom Search